59 results about "Mitiromycin" patented technology

The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula: (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group; W represents a single bond or -CH=CH-; X represents -NH- etc.; and Y represents a carbon atom or a nitrogen atom; and Z represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil; (4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin; (7) taxol; (8) carboplatin; (9) oxaliplatin; (10) capecitabine; and (11) a salt of the above-mentioned (1) to (10).

The invention discloses a chitosan-carrying mitomycin nano targeting preparation and a preparation method thereof, which relate to a medicine-carrying chitosan nano particle. The invention provides a chitosan-carrying mitomycin nano targeting preparation and a preparation method thereof. The chitosan-carrying mitomycin nano targeting preparation comprises chitosan nano particles for connecting mitomycin, which are dispersed in water. The mass ratio of mitomycin to nano particles is 1:(2-10), and the concentration of the nano particles in water is 1-20 mg / ml. The method comprises the following steps: preparing the chitosan nano particles; preparing folic acid modified nano particles; preparing PEG modified nano particles; preparing mitomycin ester succinate; and adding the mitomycin ester succinate and the chitosan nano particles into different modified nano particles, adding 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, obtaining the mitomycin-carried nano particles after reaction, and dialyzing to remove the unreacted mitomycin and other byproducts, thereby obtaining the chitosan-carrying mitomycin nano targeting preparation.

An apparatus and method for preparing a pharmaceutical for transient application includes a tray having a sealed compartment, a vial of an ophthalmic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe that are all contained together in a single package. The component parts of the apparatus are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the sealed compartment of the tray by a suction force produced by the syringe. In the tray compartment, the reconstituted drug is absorbed in at least one absorbent pad. The absorbent pads may come in multiple shapes and or / sizes. The tray is opened to remove the pad and the absorbed drug from the tray compartment for use of the pad in transient application of the drug.

The invention belongs to the technical field of microbes and specifically relates to Stenotrophomonas maltophilia and wide-spectrum maltocin synthesized from Stenotrophomonas maltophilia and application thereof. The Stenotrophomonas maltophilia is named Stenotrophomonas maltophilia S16 strain and was preserved in the China Center for Type Culture Collection with the preservation number being CCTCCM 2017431. The Stenotrophomonas maltophilia S16 strain is a new strain, and the strain can be induced by mitomycin C to produce maltocin S16. The maltocin S16 has high bactericidal activity and widebactericidal spectrum, can kill most Stenotrophomonas maltophilia as well as Escherichia coli, has resistance to protease, is relatively stable at high temperature, and has a good development and application prospect.

A multilocular liposome of mitomycin for preventing and treating tumor is prepared through dissolving the lipoid component (neutral phosphatide, cholesterol and neutral lipid) in organic solvent, dissolving mitomycin in buffering salt solution, mixing, emulsifying to obtain water-in-oil primary emulsion, adding external water phase containing isotonic regulator, stirring to become water-in-oil-in-water emulsion, and removing organic solvent.

The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.

The invention provides a mitomycin freeze-drying preparation for injection, wherein the mitomycin freeze-drying preparation is characterized in that the mitomycin freeze-drying preparation comprises the preparation raw materials by mass: 2-4 parts of mitomycin, 5-6 parts of mannitol, 500-700 parts of tertiary butanol, 10-30 parts of propylene glycol, and water added until the volume is 1000 parts. The product has no solvent residue problem and high stability.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The invention discloses a preparation method of feeder cells for rapid culture of tumor infiltrating lymphocytes. The preparation method comprises the steps that peripheral blood lymphocytes are treated by using mitomycin C to obtain the feeder cells, and then the feeder cells and pre-cultured tumor infiltrating lymphocytes are co-cultured. The efficiency of expanding the tumor infiltrating lymphocytes of the feeder cells produced by the preparation method is better than that of the feeder cells produced by gamma-ray irradiation, and meanwhile the cost of using the preparation method is significantly lowered. The preparation method is simple and easy to operate, and can be widely applied and promoted.

The invention relates to the field of medicines, in particular to a phosphorothioate modified nucleic acid aptamer medicine conjugate as well as a preparation method and an application thereof. The phosphorothioate modified nucleic acid aptamer drug conjugate comprises a drug molecule group and a phosphorus-sulfur bond substituted nucleic acid aptamer fragment, wherein the drug molecule group is selected from a mitomycin C group, and the drug molecule group is connected with the phosphorus-sulfur bond substituted nucleic acid aptamer fragment through a linking group. The phosphorothioate modified aptamer drug conjugate provided by the invention not only has all the advantages of an aptamer, but also greatly improves the enzyme digestion resistance of the aptamer-mitomycin C conjugate and prolongs the blood circulation half-life period by modifying phosphorothioate of a phosphate skeleton of an aptamer fragment; and in addition, the stability is improved, meanwhile, the original targeting property and specificity are reserved, and the high industrialization prospect is achieved.

The invention discloses a method for preparing feeder layer cells. The method provided by the invention comprises the following steps: (1) treating the isolated fibroblasts with 10 μg / ml mitomycin C, collecting the culture supernatant and adherent cells respectively; (2) treating the isolated fibroblasts The cells are treated with the culture supernatant collected in the previous step, and the adherent cells are collected; between the step (1) and the step (2), the following steps of 0 to 2 times are also included: the isolated fibroblast The cells are treated with the culture supernatant collected in the previous step, and the culture supernatant and adherent cells are collected respectively; the adherent cells obtained in each of the above steps are feeder layer cells. The method for preparing feeder layer cells provided by the invention has simple flow, economical and reliable effect. Human embryonic stem cell culture experiments show that the feeder layer cells prepared by the method can be passed on for a long time, and can effectively support the growth of human embryonic stem cells and keep them in an undifferentiated state.

The invention relates to a composition for preventing scar adhesion, a postoperative anti-adhesion material and application. Epidural scar adhesion is an important cause of postoperative lumbar surgery failure syndrome, and the invention aims to provide a drug-loaded postoperative sealing material which can seal wounds and realize stable release of drugs at the same time. The invention firstly provides the mitomycin C-IFN gamma-sodium hyaluronate conjugate for preventing scar adhesion, the conjugate can effectively inhibit scar tissue formation and slow down the drug degradation speed, and when the conjugate is applied to a polyethylene glycol sealant, the sealing effects of low swelling and rapid condensation can be achieved. The product is especially suitable for spinal surgeries such as laminectomy and the like, and has good clinical application value.

The invention provides a preparation method of an ophthalmic preparation of mitomycin C. The preparation method comprises the following steps: inclusion is carried out on mitomycin C by using hydroxypropyl-beta-cyclodextrin or a derivative thereof, the water solubility of mitomycin C is improved, an osmotic pressure regulator is added, and the solution is freeze-dried, so that the stability of the ophthalmic preparation is improved.

The invention discloses a mitomycin C cotton pad for preventing scar adhesion. With a medical cotton pad as a carrier, the medical cotton pad is immersed in a mitomycin C solution and then dried in vacuum to obtain a dried cotton pad on which mitomycin C is uniformly attached. The invention also discloses a preparation method and a use method of the mitomycin C cotton pad. According to the mitomycin C cotton pad disclosed by the invention, the processes of preparing the mitomycin C solution and shearing the cotton pad to reach a proper size in operation are avoided, operation time is saved, operation is enabled to be convenient and rapid, and risks of operation pollution are reduced.

The invention relates to the technical field of drug inhibitors, in particular to a novel PD-1 tumor immunosuppressant and a drug preparation method thereof. The immunosuppressant is prepared from byweight, 30-45 parts of PD-1 monoclonal antibody, 2-6 parts of alkaloid, 4-7 parts of antibiotic, 3-9 parts of alkylating agent, 1-5 parts of platinum agent and 5-9 parts of metabolic antagonist; the alkaloid consists of one or more of paclitaxel, vincristine and docetaxel; the antibiotic consists of one or more of epirubicin, idarubicin and mitomycin; the alkylating agent is one or two of ifosfamide and dacarbazine; the platinum agent is one or two of cisplatin and oxaliplatin; the metabolic antagonist is one or more of gemcitabine, cytarabine and tegafur. The immunosuppressant can block the interaction between PD-L1 molecules expressed on tumor cells and receptors on activated T cells, inhibit the apoptosis of the activated T cells and improve the killing capability of the tumor cells.

The present invention concerns antibody-conjugate having general structure (2):AB-[(L6)-{Z-(L1)n-(L2)o-(L3)p-(L4)q-D}xx]yy   (2)wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

Disclosed is a slow release injection agent of anticancer composition containing nitrosourea drugs and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the nitrosourea drugs are selected from Carmustine, Nimustine or Fotemustine, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or temozolomide and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The invention provides a treatment method for the de-proliferation ability of feeder cells for NK cell culture, and uses mitomycin C to process the feeder cells. The de-proliferation operation methodof the feeder cells provided by the invention has low costs, and is simple to operate and convenient to promote and use; the cell morphology of the feeder cells processed by the method remains intact,the expansion of NK cells can be better stimulated, so that the prepared NK cells have very high purity and killing activity, through detection, when the cells are cultured for 14 days, the purity ofthe NK cells reaches 94% or more, and the amplification multiple reaches 720 or more; when the effector-target ratio is 5:1, the killing activity of the NK cells on K562 cells is 60% or more; and thefeeder cells treated by the method are almost all killed by the NK cells on the fourth day of culture without post-residue residues, and the method can be applied and promoted in clinical research.

The invention discloses a YAP1 gene and application of an inhibitor in enhancing chemosensitivity of a stem cell of bladder cancer. The YAP1 gene is related to chemosensitivity of the stem cell of bladder cancer. The inhibitor where the YAP1 gene is highly expressed can improve the chemosensitivity of the stem cell of bladder cancer on chemotherapeutics mitomycin C and cis-platinum by down-regulating the expression of the YAP1 gene, so that the inhibiting rate of the chemotherapeutics mitomycin C and cis-platinum on the stem cell of bladder cancer is increased. The inhibitor where the YAP1 gene is highly expressed can be any one or more of siRNA, shRNA, dsRNA, miRNA, cDNA, a small molecular compound, a peptide and an antibody, wherein the small molecular compound is a 2-amido benzoxazole derivative.

The invention provides an anti-cancer composition. The anti-cancer composition comprises cisplatin and transplatin. The invention further provides a use method and application range of the anti-cancercomposition. According to the invention, the safety of combined application of the cisplatin and the transplatin to the interiors of animal bodies, the effectiveness of killing sensitive tumor cellsand the use method are comprehensively researched in detail. Under the conventional induction condition of drug resistance, the probability that the sensitive cells generate drug resistance is very low. In a parallel contrast experiment under the same condition, the probability that the cisplatin generates drug resistance is 87%, mitomycin-C and olaparib induce the drug resistance with high probabilities of higher than 90%, and the probability that the drug resistance is generated by the anti-cancer composition is 22%.

The invention discloses a method for establishing a transgenic removable human skin fibroblast feeder cell line. By utilizing a retrovirus-mediated gene transfer way, the production tool introduces areinforced green fluorescent protein gene, a telomerase reverse transcriptase gene and a herpes simplex virus thymidine kinase gene into human skin fibroblasts to establish a fluorescence-labeled immortalization-removable TERT + TK-D human feeder cell line. After being treated by mitomycin C, the established cell line serving as feeder cells is co-cultured with human limbal stem cells, and the culture result is compared with a culture result of 3T3 feeder cells. Transgenic fluorescence-labeled immortalization-removable human skin fibroblast feeder cells are expected to replace the 3T3 cells for corneal regeneration therapy.

The invention discloses a multifunctional mitomycin-containing cotton sheet for stopping bleeding and avoiding adhesion, which is designed according to the adhesion generating mechanism (namely local hematoma formation and fibroblast hyperplasia). The multifunctional mitomycin-containing cotton sheet has the effects of locally and precisely stopping bleeding, preventing hematoma formation and inhibiting peripheral fibroblast hyperplasia and locally and precisely preventing adhesion of scar tissues, and is a unique anti-adhesion product which is not needed to be embedded into a body in the current anti-adhesion products. The cotton sheet is a bleeding stopping tool which is most frequently used and is more effective in an operation; the cotton sheet has the advantages of disposability, capability of using after taking, convenience and rapidness as well as remarkable bleeding stopping effect and the like; the requirements for the size specifications of cotton sheets are different according to different operations, and the cotton sheets with different size specifications for meeting different operation requirements are designed, so that the aims of precisely stopping bleeding, avoiding wastes and avoiding hematoma formation are achieved; and mitomycin with a certain concentration and asiaticoside with a certain concentration are uniformly distributed in the cotton sheet disclosed by the invention, so that the cotton sheet has the effects of inhibiting fibroblast hyperplasia and preventing peripheral scar tissue hyperplasia while stopping bleeding, the curative effect of an operation is more remarkable, meanwhile, the operation time of the operation is saved, the operation is simple and rapid, and risks of the operation and environment pollution are reduced.

The invention discloses a DHA (docosahexaenoic acid)-MMC (mitomycin C) derivative. A structure formula thereof is shown in the description. The invention also discloses application of the derivative in preparing medicines for resisting pterygium, and a preparation method of the derivative. The preparation method specifically comprises the following steps of mixing DHA-NHS and a buffer solution, stirring, adding MMC, concentrating to the dry state, and separating the remained matter by silica gel column chromatography. The preparation method has the advantages that the MMC and the DHA are prepared into the larger-molecule derivative, namely the DHA-MMC, by a chemical synthesizing method, so that the molecular weight of the medicine is increased from 334 (use of single MMC) to 649, the absorbing in eyes via cornea is difficult, and the side effect in eyes is reduced; after accumulating to the conjunctiva and pterygium tissues, the derivative is gradually hydrolyzed to release the MMC to take effect; by utilizing the tumor inhibiting property and targeting property of the DHA, the selectivity and inhibiting property of the pterygium tissue of the DHA-MMC are enhanced.

The invention discloses a method for screening and identifying stress response gene expression regulatory factors. The invention develops a method for enriching protein binding genome DNA fragments toconstruct a luciferase report library for identifying clones capable of responding to environmental stress. E.coil is used as a model system for preparing a cell lysis solution and the genome DNA fragments; the cell lysis solution is mixed with the genome DNA fragments, the protein-bound DNA fragments are enriched, are separated from non-bound DNA fragments by using a membrane rotating column andare used for making the luciferase report library, and after DH5[alpha] is transformed, resistant clones are screened on an Amp antibiotic board; mitomycin C or arsenite is used for treatment, more than two times of clones induced by luciferase are identified, and correlation is proved by further analysis; and therefore, the screening and identifying method is efficient and accurate.

The invention provides a combinatorial medicine for trabeculectomy. The combinatorial medicine is prepared from mitomycin C, lidocaine, hydroxypropyl-beta-cyclodextrin, Poloxamer 407, Poloxamer 188, carbomer, mannitol, propylene glycol, sodium metabisulfite, EDTA-2Na, methylparaben, and propylparaben. The invention provides a preparation method of the combinatorial medicine for trabeculectomy andapplication of the combinatorial medicine in preparing a preparation for trabeculectomy. The preparation can prevent scars or has a surface anesthesia role in trabeculectomy. The combinatorial medicine reduces operation pollution, makes mitomycin C and lidocaine more stable, and delivers better effects in preventing scars and anesthetizing compared with the medicine using mitomycin C and lidocainealone.

Anthracyclines induce the rapid, pre-apoptotic translocation of ERP57 to the cell surface. Knock down of ERP57 inhibit the translocation of CRT, suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. In contrast, the blockade of ERP57 with blocking antibody had no effect on phagocytosis of anthracyclines-treated tumor cells by dendritic cells and their immunogenicity in mammals, such as mice. The anthracyclines-induced ERP57 translocation was mimicked by inhibition of the protein phosphatase1 / GADD34 complex. Administration of recombinant ERP57 did not restored the immunogenicity of cell death elicited by etoposide and mitomycin C, or enhanced their antitumor effects in vivo in contrast to the administration of recombinant CRT. These data identify the presence of ERP57 crucial for the translocation of CRT and to induce immunogenic cell death which will activate a anti-cancer immune responses.